See more : Indigenous Bloom Hemp Corp. (IBH.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Invex Therapeutics Ltd (IXC.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invex Therapeutics Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Shin Poong Pharm.Co.,Ltd. (019175.KS) Income Statement Analysis – Financial Results
- Tata Steel (Thailand) Public Company Limited (TSTH.BK) Income Statement Analysis – Financial Results
- Dada Nexus Limited (DADA) Income Statement Analysis – Financial Results
- Sundaram Multi Pap Limited (SUNDARAM.NS) Income Statement Analysis – Financial Results
- Trican Well Service Ltd. (TCW.TO) Income Statement Analysis – Financial Results
Invex Therapeutics Ltd (IXC.AX)
About Invex Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 1.21M | 459.09K | 182.25K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.21M | 459.09K | 182.25K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.04M | 7.40M | 2.96M | 1.14M | 1.59M | 59.88K |
| General & Administrative | 1.17M | 1.29M | 900.39K | 993.39K | 1.36M | 201.83K |
| Selling & Marketing | 137.50K | 0.00 | 0.00 | 0.00 | 0.00 | -29.45K |
| SG&A | 1.31M | 1.29M | 900.39K | 993.39K | 1.36M | 172.38K |
| Other Expenses | 0.00 | 432.35K | 208.66K | 310.08K | 0.00 | 0.00 |
| Operating Expenses | 3.35M | 8.98M | 4.24M | 2.44M | 3.41M | 232.25K |
| Cost & Expenses | 3.35M | -9.01M | -4.22M | -2.44M | 3.41M | 232.25K |
| Interest Income | 491.82K | 797.08K | 79.88K | 158.79K | 165.70K | 132.00 |
| Interest Expense | 0.00 | 0.00 | 79.88K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.13M | 8.55M | 4.03M | 2.44M | 3.25M | 381.46K |
| EBITDA | -720.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | -59.43% | -1,955.91% | -2,327.38% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.13M | -8.55M | -4.03M | -2.44M | -3.29M | -232.25K |
| Operating Income Ratio | -176.00% | -1,861.73% | -2,212.89% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -720.44K | 797.08K | 79.88K | 158.79K | -110.99K | 149.33K |
| Income Before Tax | -2.85M | -7.75M | -3.95M | -2.28M | -3.36M | -232.12K |
| Income Before Tax Ratio | -235.43% | -1,688.11% | -2,169.06% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.21M | -9.34M | -4.11M | -2.44M | -3.30M | -314.91K |
| Net Income | -1.64M | -7.75M | -3.95M | -2.28M | -3.36M | -232.12K |
| Net Income Ratio | -135.43% | -1,688.11% | -2,169.06% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.10 | -0.05 | -0.03 | -0.06 | -0.01 |
| EPS Diluted | -0.02 | -0.10 | -0.05 | -0.03 | -0.06 | -0.01 |
| Weighted Avg Shares Out | 75.31M | 75.15M | 75.15M | 75.15M | 56.17M | 23.60M |
| Weighted Avg Shares Out (Dil) | 75.31M | 75.15M | 75.15M | 75.15M | 56.17M | 23.60M |
Source: https://incomestatements.info
Category: Stock Reports